Duloxetine ameliorates acute pancreatitis-associated inflammation and modulates pain related neuroinflammatory pathways via modulation of SP-related neurokinin signaling and PAR2/TRPV1 pathways
Frontiers in Toxicology · 07.08.2026 · 8
DOI: 10.3389/ftox.2026.1891784 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Toxicology, online erschienen am 07.08.2026. Verfasst von Khaled H Almutary und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Acute pancreatitis (AP) is an inflammatory pancreatic disorder, often illustrated by neuropathic, inflammatory, and/or visceral pain. Pain is a medical indicator of pancreatic inflammation and growing evidence evokes that it exerts a significant role in AP progression via the widespread neuronal network surrounding the pancreas. Objectives evaluate the possible defensive action of duloxetine (DUX), a serotonin/norepinephrine reuptake inhibitor (SNRI), in L-arginine (L-Arg)- provoked AP and multiple organ injury (MOI), and to explore the potential mechanism of action of DUX-mediated modulation of neuroinflammatory pain in AP.
Methods
AP was induced in rats by intraperitoneal injection of L-Arg (100 mg/100 g) and two different doses of DUX (10 and 30 mg/kg) was examined.
Results
DUX improved the histopathological architecture of the pancreas, liver, lung, and kidney. Additionally, it restored the normal levels of serum pancreatic enzymes, liver enzymes, and kidney biomarkers that were significantly elevated following L-Arg administration. In addition, DUX improved tissue antioxidant state. Moreover, DUX decreased the levels of transient receptor potential cation channel subfamily V member 1 (TRPV1), proteinase-activated receptor-2 (PAR2), substance P (SP), neurokinin, trypsin, leukotriene B4 (LTB4), signal transducer and activator of transcription 3 (STAT3) and significantly reduced TNF-α expression in the pancreatic tissues.
Conclusion
DUX displayed analgesic, anti-inflammatory, and antioxidant effects. Therefore, DUX is a promising therapeutic candidate for the management of AP-related neuroinflammatory pain. The proposed analgesic and anti-inflammatory mechanisms of DUX may be linked to the modulation of SP related NK signaling and PAR2/TRPV1 pathways pointing to a possible role for these pathways in the observed beneficial action of DUX.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.
- Majmaah University, Majmaah, Saudi Arabia.
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Mansoura National University, Gamasa, Egypt.
- Future Studies and Risks Management & National Committee of Drugs, Academy of Scientific Research, Ministry of Higher Education, Elsayeda Zeinab, Egypt.
- Faculty of Health Science Technology, Mansoura National University, Gamasa, Egypt.
Zitieren
APA
Almutary, K. H., Elsheakh, A. R., Nader, M. A., & Zaghloul, M. S. (2026). Duloxetine ameliorates acute pancreatitis-associated inflammation and modulates pain related neuroinflammatory pathways via modulation of SP-related neurokinin signaling and PAR2/TRPV1 pathways. Frontiers in Toxicology, 8. https://doi.org/10.3389/ftox.2026.1891784
Vancouver
Almutary KH, Elsheakh AR, Nader MA, Zaghloul MS. Duloxetine ameliorates acute pancreatitis-associated inflammation and modulates pain related neuroinflammatory pathways via modulation of SP-related neurokinin signaling and PAR2/TRPV1 pathways. Frontiers in Toxicology. 2026;8. doi:10.3389/ftox.2026.1891784
BibTeX
@article{Almutary2026,
author = {Almutary, Khaled H and Elsheakh, Ahmed R and Nader, Manar A and Zaghloul, Marwa S},
title = {Duloxetine ameliorates acute pancreatitis-associated inflammation and modulates pain related neuroinflammatory pathways via modulation of SP-related neurokinin signaling and PAR2/TRPV1 pathways},
journal = {Frontiers in Toxicology},
year = {2026},
volume = {8},
doi = {10.3389/ftox.2026.1891784}
}
EUVIMED